BRPI0708784A2 - análise de interação de ácidos nucléicos - Google Patents

análise de interação de ácidos nucléicos Download PDF

Info

Publication number: BRPI0708784A2
Authority: BR; Brazil
Prior art keywords: polynucleotide; marker; oligonucleotide; polynucleotides; nucleic acid
Prior art date: 2006-03-13

Application number

BRPI0708784-5A

Other languages

English (en)

Portuguese (pt)

Inventor

Yijun Ruan

Melissa Jane Fullwood

Chia Lin Wei

Original Assignee

Agency Science Tech & Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-03-13

Filing date

2007-03-09

Publication date

2011-07-12

2007-03-09 Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res

2011-07-12 Publication of BRPI0708784A2 publication Critical patent/BRPI0708784A2/pt

Links

150000007523 nucleic acids Chemical class 0.000 title claims abstract description 69
102000039446 nucleic acids Human genes 0.000 title claims abstract description 52
108020004707 nucleic acids Proteins 0.000 title claims abstract description 52
238000012482 interaction analysis Methods 0.000 title abstract description 5
102000040430 polynucleotide Human genes 0.000 claims abstract description 271
108091033319 polynucleotide Proteins 0.000 claims abstract description 271
239000002157 polynucleotide Substances 0.000 claims abstract description 271
239000003550 marker Substances 0.000 claims abstract description 202
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 176
238000000034 method Methods 0.000 claims abstract description 94
108091008146 restriction endonucleases Proteins 0.000 claims description 138
108020004414 DNA Proteins 0.000 claims description 109
239000011230 binding agent Substances 0.000 claims description 68
239000013598 vector Substances 0.000 claims description 57
108090000623 proteins and genes Proteins 0.000 claims description 53
239000012634 fragment Substances 0.000 claims description 47
239000003446 ligand Substances 0.000 claims description 47
108010077544 Chromatin Proteins 0.000 claims description 46
210000003483 chromatin Anatomy 0.000 claims description 46
238000012163 sequencing technique Methods 0.000 claims description 43
102000004169 proteins and genes Human genes 0.000 claims description 41
210000000349 chromosome Anatomy 0.000 claims description 35
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 30
238000002487 chromatin immunoprecipitation Methods 0.000 claims description 27
102000004190 Enzymes Human genes 0.000 claims description 22
108090000790 Enzymes Proteins 0.000 claims description 22
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 15
238000013507 mapping Methods 0.000 claims description 15
108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
238000011144 upstream manufacturing Methods 0.000 claims description 13
238000003780 insertion Methods 0.000 claims description 10
230000037431 insertion Effects 0.000 claims description 10
238000003776 cleavage reaction Methods 0.000 claims description 7
230000007017 scission Effects 0.000 claims description 7
238000001114 immunoprecipitation Methods 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 4
230000003993 interaction Effects 0.000 description 37
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
210000004027 cell Anatomy 0.000 description 33
239000013612 plasmid Substances 0.000 description 26
238000003752 polymerase chain reaction Methods 0.000 description 26
239000002773 nucleotide Substances 0.000 description 25
125000003729 nucleotide group Chemical group 0.000 description 25
239000000872 buffer Substances 0.000 description 20
238000009739 binding Methods 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
238000010367 cloning Methods 0.000 description 16
239000000499 gel Substances 0.000 description 16
230000027455 binding Effects 0.000 description 15
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
230000003321 amplification Effects 0.000 description 14
238000003199 nucleic acid amplification method Methods 0.000 description 14
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
238000013459 approach Methods 0.000 description 12
239000000203 mixture Substances 0.000 description 12
108091023040 Transcription factor Proteins 0.000 description 11
102000040945 Transcription factor Human genes 0.000 description 11
239000000539 dimer Substances 0.000 description 11
230000001404 mediated effect Effects 0.000 description 11
238000000746 purification Methods 0.000 description 11
230000008439 repair process Effects 0.000 description 11
239000012149 elution buffer Substances 0.000 description 10
230000002068 genetic effect Effects 0.000 description 10
239000000463 material Substances 0.000 description 10
108010033040 Histones Proteins 0.000 description 9
108010042407 Endonucleases Proteins 0.000 description 8
229960003964 deoxycholic acid Drugs 0.000 description 8
239000000284 extract Substances 0.000 description 8
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 8
238000000527 sonication Methods 0.000 description 8
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 8
239000011534 wash buffer Substances 0.000 description 8
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
102000003960 Ligases Human genes 0.000 description 7
108090000364 Ligases Proteins 0.000 description 7
101150101095 Mmp12 gene Proteins 0.000 description 7
230000001580 bacterial effect Effects 0.000 description 7
239000011324 bead Substances 0.000 description 7
230000002759 chromosomal effect Effects 0.000 description 7
210000001671 embryonic stem cell Anatomy 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
102000052510 DNA-Binding Proteins Human genes 0.000 description 6
239000007995 HEPES buffer Substances 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
229920004890 Triton X-100 Polymers 0.000 description 6
239000013504 Triton X-100 Substances 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000001514 detection method Methods 0.000 description 6
238000004520 electroporation Methods 0.000 description 6
238000005516 engineering process Methods 0.000 description 6
238000001976 enzyme digestion Methods 0.000 description 6
HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical compound C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 6
238000002493 microarray Methods 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000003908 quality control method Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
102000053602 DNA Human genes 0.000 description 5
102000004533 Endonucleases Human genes 0.000 description 5
102000006947 Histones Human genes 0.000 description 5
108091005461 Nucleic proteins Proteins 0.000 description 5
108010064978 Type II Site-Specific Deoxyribonucleases Proteins 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000029087 digestion Effects 0.000 description 5
238000000605 extraction Methods 0.000 description 5
238000001502 gel electrophoresis Methods 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
210000004940 nucleus Anatomy 0.000 description 5
230000008707 rearrangement Effects 0.000 description 5
239000000523 sample Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000009466 transformation Effects 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
229920001817 Agar Polymers 0.000 description 4
108091029523 CpG island Proteins 0.000 description 4
102000012410 DNA Ligases Human genes 0.000 description 4
108010061982 DNA Ligases Proteins 0.000 description 4
108700020911 DNA-Binding Proteins Proteins 0.000 description 4
108010067770 Endopeptidase K Proteins 0.000 description 4
101710163270 Nuclease Proteins 0.000 description 4
230000001464 adherent effect Effects 0.000 description 4
239000008272 agar Substances 0.000 description 4
239000011543 agarose gel Substances 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
238000005520 cutting process Methods 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
239000000945 filler Substances 0.000 description 4
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000003426 interchromosomal effect Effects 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
230000002441 reversible effect Effects 0.000 description 4
229940063673 spermidine Drugs 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
238000012546 transfer Methods 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
102100031780 Endonuclease Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
238000004132 cross linking Methods 0.000 description 3
238000012869 ethanol precipitation Methods 0.000 description 3
239000000834 fixative Substances 0.000 description 3
230000014509 gene expression Effects 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
238000005304 joining Methods 0.000 description 3
239000003068 molecular probe Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000005945 translocation Effects 0.000 description 3
229930024421 Adenine Natural products 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
229920000856 Amylose Polymers 0.000 description 2
238000007450 ChIP-chip Methods 0.000 description 2
239000003298 DNA probe Substances 0.000 description 2
238000001712 DNA sequencing Methods 0.000 description 2
101710096438 DNA-binding protein Proteins 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
102000005720 Glutathione transferase Human genes 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
108060003393 Granulin Proteins 0.000 description 2
102100039869 Histone H2B type F-S Human genes 0.000 description 2
101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 2
102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
239000006142 Luria-Bertani Agar Substances 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
101710120037 Toxin CcdB Proteins 0.000 description 2
208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
229960000643 adenine Drugs 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
229960003180 glutathione Drugs 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
238000007747 plating Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
239000011535 reaction buffer Substances 0.000 description 2
230000010076 replication Effects 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
238000003260 vortexing Methods 0.000 description 2
CUJMXIQZWPZMNQ-XYYGWQPLSA-N 13,14-dihydro-15-oxo-prostaglandin E2 Chemical compound CCCCCC(=O)CC[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O CUJMXIQZWPZMNQ-XYYGWQPLSA-N 0.000 description 1
241001156002 Anthonomus pomorum Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108020005031 Concatenated DNA Proteins 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
-1 DNA Chemical class 0.000 description 1
238000013382 DNA quantification Methods 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108700024394 Exon Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
208000034951 Genetic Translocation Diseases 0.000 description 1
102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102100037850 Interferon gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
108020004518 RNA Probes Proteins 0.000 description 1
239000003391 RNA probe Substances 0.000 description 1
101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
102000001218 Rec A Recombinases Human genes 0.000 description 1
108010055016 Rec A Recombinases Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
108010084455 Zeocin Proteins 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000000981 basic dye Substances 0.000 description 1
239000012148 binding buffer Substances 0.000 description 1
239000012620 biological material Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000032823 cell division Effects 0.000 description 1
210000003855 cell nucleus Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
108091006090 chromatin-associated proteins Proteins 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
230000002559 cytogenic effect Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000008482 dysregulation Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
108010026638 endodeoxyribonuclease FokI Proteins 0.000 description 1
230000001973 epigenetic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000010195 expression analysis Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003999 initiator Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
102000044158 nucleic acid binding protein Human genes 0.000 description 1
108700020942 nucleic acid binding protein Proteins 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
230000008520 organization Effects 0.000 description 1
LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
230000037361 pathway Effects 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000010349 pulsation Effects 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000005096 rolling process Methods 0.000 description 1
238000010079 rubber tapping Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000004513 sizing Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000005400 testing for adjacent nuclei with gyration operator Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
238000012795 verification Methods 0.000 description 1
238000012800 visualization Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6804—Nucleic acid analysis using immunogens
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
- C12Q2521/313—Type II endonucleases, i.e. cutting outside recognition site
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/101—Crosslinking agents, e.g. psoralen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/131—Modifications characterised by incorporating a restriction site
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/191—Modifications characterised by incorporating an adaptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/197—Modifications characterised by incorporating a spacer/coupling moiety
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Analytical Chemistry (AREA)
Plant Pathology (AREA)
Bioinformatics & Computational Biology (AREA)
Pathology (AREA)
Crystallography & Structural Chemistry (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

BRPI0708784-5A 2006-03-13 2007-03-09 análise de interação de ácidos nucléicos BRPI0708784A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11/373,519 US8071296B2 (en)	2006-03-13	2006-03-13	Nucleic acid interaction analysis
US11/373,519		2006-03-13
PCT/SG2007/000069 WO2007106047A1 (fr)	2006-03-13	2007-03-09	Analyse d'interaction d'acide nucléique

Publications (1)

Publication Number	Publication Date
BRPI0708784A2 true BRPI0708784A2 (pt)	2011-07-12

Family

ID=38232601

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0708784-5A BRPI0708784A2 (pt)	2006-03-13	2007-03-09	análise de interação de ácidos nucléicos

Country Status (10)

Country	Link
US (1)	US8071296B2 (fr)
EP (1)	EP1835038B1 (fr)
JP (1)	JP2007289152A (fr)
KR (1)	KR20080102301A (fr)
CN (1)	CN101410516B (fr)
AU (1)	AU2007225499A1 (fr)
BR (1)	BRPI0708784A2 (fr)
CA (1)	CA2647935A1 (fr)
TW (1)	TW200813220A (fr)
WO (1)	WO2007106047A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2202322A1 (fr)	2003-10-31	2010-06-30	AB Advanced Genetic Analysis Corporation	Procédés de production d'étiquette appariée à partir d'une séquence d'acide nucléique et leurs procédés d'utilisation
US8071296B2 (en)	2006-03-13	2011-12-06	Agency For Science, Technology And Research	Nucleic acid interaction analysis
CN102016068A (zh)	2008-01-09	2011-04-13	生命科技公司	制备用于核酸测序的配对标签文库的方法
WO2012044847A1 (fr)	2010-10-01	2012-04-05	Life Technologies Corporation	Adaptateurs d'acides nucléiques et leurs utilisations
US8263367B2 (en) *	2008-01-25	2012-09-11	Agency For Science, Technology And Research	Nucleic acid interaction analysis
US9434985B2 (en)	2008-09-25	2016-09-06	University Of Massachusetts	Methods of identifying interactions between genomic loci
US8481699B2 (en) *	2009-07-14	2013-07-09	Academia Sinica	Multiplex barcoded Paired-End ditag (mbPED) library construction for ultra high throughput sequencing
US8574832B2 (en) *	2010-02-03	2013-11-05	Massachusetts Institute Of Technology	Methods for preparing sequencing libraries
US9029103B2 (en) *	2010-08-27	2015-05-12	Illumina Cambridge Limited	Methods for sequencing polynucleotides
US8663919B2 (en)	2011-05-18	2014-03-04	Life Technologies Corporation	Chromosome conformation analysis
CN102427171A (zh) *	2011-07-29	2012-04-25	中国兵器工业第二○六研究所	Ka波段平板缝隙阵天线单脉冲馈电网络
WO2013070167A1 (fr) *	2011-11-10	2013-05-16	Neus Visa	Utilisation d'un complexe adn-anticorps synthétique en tant que référence externe pour une immunoprécipitation de chromatine
GB2519255B (en)	2013-02-01	2016-01-06	Univ California	Methods for genome assembly and haplotype phasing
US9411930B2 (en)	2013-02-01	2016-08-09	The Regents Of The University Of California	Methods for genome assembly and haplotype phasing
KR102310441B1 (ko) *	2013-09-05	2021-10-07	더 잭슨 래보라토리	Rna-염색질 상호작용 분석용 조성물 및 이의 용도
US10526641B2 (en)	2014-08-01	2020-01-07	Dovetail Genomics, Llc	Tagging nucleic acids for sequence assembly
KR102721363B1 (ko)	2015-02-17	2024-10-23	더브테일 제노믹스 엘엘씨	핵산 서열 어셈블리
WO2016154540A1 (fr)	2015-03-26	2016-09-29	Dovetail Genomics Llc	Conservation de la liaison physique dans le stockage d'adn
US12018314B2 (en)	2015-07-02	2024-06-25	Arima Genomics, Inc.	Accurate molecular deconvolution of mixture samples
WO2017059239A1 (fr) *	2015-10-02	2017-04-06	Arizona Board Of Regents On Behalf Of Arizona State University	Procédés de traitement de matrices biopolymères
AU2016341198B2 (en)	2015-10-19	2023-03-09	Dovetail Genomics, Llc	Methods for genome assembly, haplotype phasing, and target independent nucleic acid detection
US10975417B2 (en)	2016-02-23	2021-04-13	Dovetail Genomics, Llc	Generation of phased read-sets for genome assembly and haplotype phasing
SG11201809996QA (en)	2016-05-12	2018-12-28	Agency Science Tech & Res	Ribonucleic acid (rna) interactions
CN109477101B (zh)	2016-05-13	2022-11-18	多弗泰尔基因组学有限责任公司	从保存的样品中回收长范围连锁信息
WO2019152543A1 (fr)	2018-01-31	2019-08-08	Dovetail Genomics, Llc	Préparation d'échantillon pour récupération de liaison d'adn
CN113272441A (zh)	2018-11-20	2021-08-17	阿瑞玛基因组学公司	保留空间邻近连续性信息的制备核酸的方法和组合物
CN119139470A (zh) *	2024-06-14	2024-12-17	北京市肿瘤防治研究所	葡萄球菌属在肿瘤转移中的作用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4766072A (en)	1985-07-17	1988-08-23	Promega Corporation	Vectors for in vitro production of RNA copies of either strand of a cloned DNA sequence
US5866330A (en)	1995-09-12	1999-02-02	The Johns Hopkins University School Of Medicine	Method for serial analysis of gene expression
US6136537A (en) *	1998-02-23	2000-10-24	Macevicz; Stephen C.	Gene expression analysis
US6054276A (en)	1998-02-23	2000-04-25	Macevicz; Stephen C.	DNA restriction site mapping
DE60045796D1 (de)	1999-09-01	2011-05-12	Whitehead Biomedical Inst	Gesamt-chromosom analyse von protein-dns wechselwirkungen
US7244559B2 (en)	1999-09-16	2007-07-17	454 Life Sciences Corporation	Method of sequencing a nucleic acid
WO2001048247A2 (fr)	1999-12-29	2001-07-05	Arch Development Corporation	Procede servant a generer des fragments d'adnc plus longs a partir d'etiquettes de sage afin d'identifier des genes
WO2002010438A2 (fr)	2000-07-28	2002-02-07	The Johns Hopkins University	Analyse en serie de l'expression de transcrits au moyen de longs marqueurs
US20060292560A1 (en)	2000-08-14	2006-12-28	Robert Burgess	Transcription factor target gene discovery
GB0228289D0 (en)	2002-12-04	2003-01-08	Genome Inst Of Singapore Nat U	Method
WO2004065628A1 (fr)	2003-01-21	2004-08-05	Guoliang Fu	Detection multiplex quantitative d'acides nucleiques
AU2004257191B2 (en)	2003-07-03	2009-05-07	The Regents Of The University Of California	Genome mapping of functional DNA elements and cellular proteins
US8222005B2 (en)	2003-09-17	2012-07-17	Agency For Science, Technology And Research	Method for gene identification signature (GIS) analysis
EP2202322A1 (fr) *	2003-10-31	2010-06-30	AB Advanced Genetic Analysis Corporation	Procédés de production d'étiquette appariée à partir d'une séquence d'acide nucléique et leurs procédés d'utilisation
CA2557841A1 (fr) *	2004-02-27	2005-09-09	President And Fellows Of Harvard College	Sequencage in situ en fluorescence de billes par la technologie polony
US20080096255A1 (en)	2004-07-02	2008-04-24	Matthias Harbers	Method for Preparing Sequence Tags
US8005621B2 (en)	2004-09-13	2011-08-23	Agency For Science Technology And Research	Transcript mapping method
WO2007057785A2 (fr)	2005-05-24	2007-05-24	Rolf Ohisson	Methodes d'analyse d'interactions entre au moins sequences d'acides nucleiques
US8428882B2 (en)	2005-06-14	2013-04-23	Agency For Science, Technology And Research	Method of processing and/or genome mapping of diTag sequences
PL1899488T3 (pl)	2005-07-04	2016-03-31	Erasmus Univ Medical Center	Test uchwytu konformacji chromosomu na czipie (4C)
US8071296B2 (en)	2006-03-13	2011-12-06	Agency For Science, Technology And Research	Nucleic acid interaction analysis

2006
- 2006-03-13 US US11/373,519 patent/US8071296B2/en not_active Expired - Fee Related
2007
- 2007-03-08 TW TW096108083A patent/TW200813220A/zh unknown
- 2007-03-09 BR BRPI0708784-5A patent/BRPI0708784A2/pt not_active Application Discontinuation
- 2007-03-09 KR KR1020087024855A patent/KR20080102301A/ko not_active Ceased
- 2007-03-09 AU AU2007225499A patent/AU2007225499A1/en not_active Abandoned
- 2007-03-09 CN CN2007800091831A patent/CN101410516B/zh not_active Expired - Fee Related
- 2007-03-09 WO PCT/SG2007/000069 patent/WO2007106047A1/fr not_active Ceased
- 2007-03-09 CA CA002647935A patent/CA2647935A1/fr not_active Abandoned
- 2007-03-12 EP EP07251006.8A patent/EP1835038B1/fr not_active Not-in-force
- 2007-03-13 JP JP2007063117A patent/JP2007289152A/ja active Pending

Also Published As

Publication number	Publication date
US8071296B2 (en)	2011-12-06
EP1835038B1 (fr)	2014-06-04
TW200813220A (en)	2008-03-16
AU2007225499A1 (en)	2007-09-20
WO2007106047A1 (fr)	2007-09-20
CN101410516B (zh)	2012-05-30
WO2007106047A8 (fr)	2009-07-23
EP1835038A1 (fr)	2007-09-19
CN101410516A (zh)	2009-04-15
KR20080102301A (ko)	2008-11-24
JP2007289152A (ja)	2007-11-08
CA2647935A1 (fr)	2007-09-20
US20070238101A1 (en)	2007-10-11

Publication	Publication Date	Title
BRPI0708784A2 (pt)	2011-07-12	análise de interação de ácidos nucléicos
US10640818B2 (en)	2020-05-05	Compositions and methods for selection of nucleic acids
EP3633047B1 (fr)	2022-12-28	Procédés de séquenage d' acides nucléiques basé sur un enrichissement d'acides nucléiques
US20200109396A1 (en)	2020-04-09	Compositions and methods for enrichment of nucleic acids
CN101395281B (zh)	2013-05-01	用于核酸作图和鉴定核酸的精细结构变化的方法以及用途
EP1954818B2 (fr)	2021-01-20	Procede pour preparer des bibliotheques de polynucleotides matrices
EP1682680B2 (fr)	2018-03-21	Procedes de production d'une etiquette appariee a partir d'une sequence d'acides nucleiques et methodes d'utilisation associees
US7553947B2 (en)	2009-06-30	Method for gene identification signature (GIS) analysis
US20070172839A1 (en)	2007-07-26	Asymmetrical adapters and methods of use thereof
AU2021204166A1 (en)	2021-07-15	Reagents, kits and methods for molecular barcoding
WO2013192292A1 (fr)	2013-12-27	Analyse de séquence d'acide nucléique spécifique d'un locus multiplexe massivement parallèle
EP4159872A1 (fr)	2023-04-05	Marquage de l'adn
US20240384264A1 (en)	2024-11-21	Guide Strand Library Construction and Methods of Use Thereof
JP2002537774A (ja)	2002-11-12	多型ｄｎａフラグメントおよびその使用
EP3927717A1 (fr)	2021-12-29	Construction de banques de brins guides et procédés d'utilisation associés
JP4446746B2 (ja)	2010-04-07	ポリヌクレオチドの並行配列決定のための一定長シグネチャー
CN115820824A (zh)	2023-03-21	一种植物全基因组rna-染色质互作的检测方法
US20180282799A1 (en)	2018-10-04	Targeted locus amplification using cloning strategies

Legal Events

Date	Code	Title	Description
2012-04-03	B11A	Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
2012-07-31	B11Y	Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]